Evidence map›Paper›PMID 34272319›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with

Daniel Roth, Johan Gustafsson, Carl Fredrik Warfvinge, Anna Sundlöv, Anna Åkesson, Jan Tennvall, Katarina Sjögreen Gleisner

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. Safety and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025
    Trial
  3. Dosimetry of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  4. Patient Survival and Its Relation to Tumor Absorbed Dose in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  5. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  6. Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  7. Article
  8. Article
  9. Continuous βClinical and translational radiation oncology · 2025
    Article
  10. CanJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  11. Multicycle Dosimetric Behavior and Dose-Effect Relationships in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Mathematic Modeling of Tumor Growth During [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel RothDepartment of Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Johan GustafssonDepartment of Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Carl Fredrik WarfvingeDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; and.
Anna SundlövDepartment of Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Anna ÅkessonClinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden.
Jan TennvallDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; and.
Katarina Sjögreen GleisnerDepartment of Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden; katarina.sjogreen_gleisner@med.lu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor dosimetry was performed for

Indexed as

Neuroendocrine TumorsOrganometallic CompoundsHumansOctreotideOvertreatmentPositron-Emission TomographyRadiometryRadionuclide ImagingRadiopharmaceuticalscopper dotatate CU-64OctreotideOrganometallic CompoundsRadiopharmaceuticals177Lu-DOTATATEabsorbed dosefractionationneuroendocrine tumors

Identifiers

PMID34272319
PMCPMC8978188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.